Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRI
Key facts
- Who runs it
- Xemed LLC
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 27 people enrolled
- Started
- 20 Oct 2023
- Ended
- 11 Sept 2025
- Type of study
- Interventional
- Treatments tested
- MagniXene Hyperpolarized Xenon MRI
- Record updated
- 30 September 2025
- Why it stopped
- Regulatory Compliance
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- COPD patients scheduled to receive endobronchial valve therapy
- Patient is conscious, cooperative and agrees to return for scheduled visits and tests
Who cannot take part
- Active drug or alcohol dependence
- A language, communication, cognitive or behavioral impairment that might interfere with fully informed participation in the study
- History of uncompensated organ failure (i.e. organ failure that is not stabilized through medical intervention), which will be assessed by the PI
- Patients less than 18 years old
- Patients known to be pregnant - a positive pregnancy test will be used to respectively exclude pregnant patients
- Any known contraindication to MRI examination
- Anyone with an implanted metal device
- Inability to provide informed consent
- Homelessness or other unstable living situation
- Claustrophobia
- Subjects weighting more than 300 pounds
- Subjects with chest size larger than the bore of MRI machine from the study
Where in United States
- Hospital of the University of PennsylvaniaPhiladelphia, United States
About the trial
What the trial wants to find out
This study proposes to use hyperpolarized xenon-129 Magnetic Resonance Imaging (MRI) to study lung function of COPD patients who will receive endobronchial valve (EBV) therapy as part of their clinical standard-of-care. Once inhaled, HP xenon can provide information to imagers regarding functionality across specific regions of the lungs through the assessment of the replacement of air during the normal breathing cycle, how much oxygen is in the airspaces, and if the normal spongy tissue structure has been compromised by lung disease. Pre- (baseline) and post-EBV (follow-up) lung function imaging with HPXe will potentially lead to be better understand disease progression and treatment mechanism.
The group in the trial
- Hyperpolarized Xenon MRI assessment of lung function in endobronchial valve treated COPD patientsTreatment being tested
Volunteer patients scheduled for receiving endobronchial valve treatment as part of clinical care will be imaged with hyperpolarized xenon prior and post EBV for assessing lung function and improvement.
Treatment: MagniXene Hyperpolarized Xenon MRI
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 September 2025